Developing a new animal model to produce high-value antibodies
Research and Development to Establish a Small Animal Model as a Significant Resource of High-Value Single-Domain Antibodies
['FUNDING_SBIR_2'] · INGENIOUS TARGETING LABORATORY, INC. · NIH-10909041
This study is working on creating special mice that can help make better antibodies for new medicines, which could lead to improved treatments for patients.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INGENIOUS TARGETING LABORATORY, INC. (nih funded) |
| Locations | 1 site (RONKONKOMA, UNITED STATES) |
| Trial ID | NIH-10909041 on ClinicalTrials.gov |
What this research studies
This research focuses on creating genetically modified mouse models to produce and optimize high-value single-domain antibodies, which are crucial for developing biological drugs. The project aims to overcome the limitations of traditional antibody production methods by utilizing camelid-based antibodies known for their superior binding properties. By establishing a murine platform, the researchers hope to enhance the efficiency and effectiveness of antibody generation, which could lead to better therapeutic options. Patients may benefit from advancements in biologics that arise from this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals with conditions that could be treated with advanced biologics, such as autoimmune diseases or cancers.
Not a fit: Patients with conditions that do not respond to antibody-based therapies may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and targeted biological drugs for various diseases.
How similar studies have performed: Other research has shown promise in using genetically modified animal models for antibody production, indicating that this approach has potential for success.
Where this research is happening
RONKONKOMA, UNITED STATES
- INGENIOUS TARGETING LABORATORY, INC. — RONKONKOMA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KIRILOV, MILEN — INGENIOUS TARGETING LABORATORY, INC.
- Study coordinator: KIRILOV, MILEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus